• Nanoform set out plans to position its CESS technology as a cost leader versus spray-dried amorphous solid dispersions.
• Strategy centers on expanding clinical and commercial GMP CESS capacity in Helsinki to support multi-ton annual production.
• Focus on lowering cost of goods through higher yields, reduced excipient use, simplified downstream processing, lower capital requirements.
• Commercial push targets higher drug loading to cut pill burden while matching or improving bioavailability versus spray-dried ASDs.
• Manufacturing roadmap emphasizes recycled pharmaceutical-grade CO₂ processing to reduce solvent use and improve sustainability economics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanoform Finland plc published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.